Tamtam Try Tamtam free
Agilent Technologies logo

Agilent Technologies account plan

Developing scientific solutions

At a glance

Agilent Technologies sells lab instruments, software, services, consumables and CDMO capacity; FY2025 revenue $6,948 million, about 18,200 staff.

Agilent Technologies supplies instruments, software, services and consumables for the whole laboratory workflow, plus a specialty CDMO, to pharma and biopharma, diagnostics and clinical labs, chemicals and advanced materials, environmental, food, and academic and government customers. It sells mainly through a direct sales force, with distributors and e-commerce, and runs R&D and manufacturing in the United States, Europe and Asia Pacific. In FY2025 (year to October 31, 2025) net revenue was $6,948 million, up 7%, and net income $1,303 million; the United States accounted for $2,342 million and China including Hong Kong for $1,224 million. Headcount was about 18,200 at July 31, 2026. Padraig McDonnell has been CEO since May 2024.

Business units

Strategic priorities

Ignite transformation
Ignite, announced in late 2024, started with strategic pricing, procurement and tariff mitigation; pricing delivered about 200 basis points in Q3 FY2026, past the initial target of more than 100 basis points.
Long-range growth targets
The long-range plan aims for 5 to 7% core revenue growth a year and double-digit EPS growth.
Pharma and reshoring
Management sizes the pharma reshoring opportunity at about $1 billion through 2030 and expects to win at least one third; reshoring orders came from five of the top 10 pharma companies in Q3 FY2026.
Advanced Therapeutics capacity
Expanding nucleic acid therapeutics manufacturing in Frederick, Colorado; Train C should generate revenue next spring, with 75% of available FY27 capacity under purchase orders.
Software, automation and AI
Building software and informatics, lab automation and a digital-lab ecosystem; an enterprise AI strategy runs with OpenAI and BCG X and an Agilent AI Center of Excellence.
Instrument replacement and new products
Riding the LC and GC replacement cycle with launches such as the 9500 triple quad ICP-MS, the 8890B and 8860B GCs and the Altura column family.

Latest results

In Q3 fiscal 2026 (quarter to July 31, 2026) net revenue was $1,878 million, up 8% with no currency impact, and nine-month revenue $5,511 million, also up 8%. All three segments and all regions grew; pharma grew 12% and China 9%. GAAP operating margin rose to 23.6% from 20.7% a year earlier, with IEEPA tariff refunds adding about 1 point, and Q3 net income was $362 million. Agilent raised FY2026 guidance to revenue of $7.49 to $7.51 billion (core growth 5.8% to 6%) and EPS of $6.18 to $6.21, with capex of about $450 million.

Investments and deals

Biocare acquisition
Acquired Biocare (BC Midco I) on June 24, 2026 for $950 million net to expand pathology, funded partly by $600 million of 4.90% senior notes due 2032.
BIOVECTRA acquisition
Bought BIOVECTRA on September 20, 2024 for $915 million in cash, adding microbial fermentation, bioreagents and highly potent APIs to the CDMO.
Frederick, Colorado capacity
Capex was $407 million in FY2025; about $450 million is expected in FY2026, mainly for advanced therapeutics capacity in Frederick, Colorado.
Restructuring plans
The FY25 plan now targets about $90 million to $95 million of annual savings; a new FY26 plan carries a $15 million charge and about $30 million to $35 million of annual savings.
Capital return
Buybacks of $295 million in the first nine months of FY2026, with about $1,654 million left under the 2024 program, and a quarterly dividend of $0.255 per share.

Challenges and risks

Tariffs and trade
Higher tariffs and shipping costs compressed FY2025 margins; IEEPA refund claims are filed but their timing is uncertain, and U.S.-China relations remain a named risk.
Academic and government spending
Academia and Government was the only end market to decline in FY2025 ($540 million) and fell to $128 million in Q3 FY2026, with U.S. federal funding a named risk.
Rising tax rate
Pillar Two top-up taxes lifted the Q3 FY2026 effective tax rate to 18.5% from 8.2%.
Competition and regulation
Agilent competes with Thermo Fisher, Danaher, Waters, Shimadzu and others, and must comply with FDA and EU IVDR rules.
Inventory and supply
Inventory days on hand rose to 120 at July 31, 2026 (107 a year earlier) on strategic purchases to mitigate tariff risk and secure supply.

What leadership says

“make no mistake our extraordinary q3 results are no accident nor are they purely a function of improving end markets”

Padraig McDonnell, President and CEO · Q3 fiscal 2026 earnings call, August 26, 2026

“about 1 billion through 2030, and we expect to at least win one third of that”

Padraig McDonnell, President and CEO · On pharma reshoring, Q3 fiscal 2026 earnings call, August 26, 2026

“We are not aiming to be a generalist CDMO. We are building a specialized, high-capability business in strategic swim lanes.”

Padraig McDonnell, Chief Executive Officer · GBR US Life Sciences 2025 interview

“We have large M&A ambitions. BIOVECTRA is just the beginning.”

Padraig McDonnell, President and CEO · GBR US Life Sciences 2025 interview

Where a supplier can help

Capacity build-out in Colorado
The Frederick, Colorado advanced therapeutics expansion and Train C start-up create needs for GMP equipment, engineering, validation and staffing suppliers.
Integrating Biocare
The Biocare pathology acquisition calls for integration support in systems, supply chain and commercial operations within Life Sciences and Diagnostics Markets.
Ignite pricing and procurement
Ignite's focus on pricing, procurement and tariff mitigation opens doors for sourcing, pricing analytics and supply chain tools that support margin goals.
AI and digital lab
The enterprise AI strategy and digital-lab ecosystem point to demand for data, connectivity and automation partners that can show clear impact.
Reshoring demand
Pharma reshoring orders give suppliers of lab installation, compliance and service capacity a way to support Agilent's push to win a share of that opportunity.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Agilent Technologies?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Agilent Technologies

What does Agilent Technologies do?

Agilent sells laboratory instruments, software, services and consumables, and runs a specialty CDMO, for pharma, diagnostics, chemicals, environmental, food and academic labs. It is organised in three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.

What is Agilent's revenue?

Net revenue was $6,948 million in FY2025 (year to October 31, 2025), up 7%. For FY2026 Agilent guides to $7.49 to $7.51 billion.

How many employees does Agilent have?

About 18,200 at July 31, 2026, up from about 18,100 at October 31, 2025, mainly due to the Biocare acquisition.

Who leads Agilent Technologies?

Padraig McDonnell has been President and CEO since May 2024; Adam Elinoff has been CFO since November 2025.

What is Agilent's strategy?

Agilent runs the Ignite transformation, targets 5 to 7% core revenue growth a year and double-digit EPS growth, and invests in advanced therapeutics capacity, pathology, software and AI, and M&A.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)